Search alternatives:
larger decrease » marked decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
larger decrease » marked decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
3021
Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay
Published 2025“…By developing a delivery vector that specifically targets circulating malignant cells (CMCs) in patient blood samples, we established an ex vivo platform to study the dynamic interplay between patient-derived cancer cells and immune cells. …”
-
3022
Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay
Published 2025“…By developing a delivery vector that specifically targets circulating malignant cells (CMCs) in patient blood samples, we established an ex vivo platform to study the dynamic interplay between patient-derived cancer cells and immune cells. …”
-
3023
Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay
Published 2025“…By developing a delivery vector that specifically targets circulating malignant cells (CMCs) in patient blood samples, we established an ex vivo platform to study the dynamic interplay between patient-derived cancer cells and immune cells. …”
-
3024
Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay
Published 2025“…By developing a delivery vector that specifically targets circulating malignant cells (CMCs) in patient blood samples, we established an ex vivo platform to study the dynamic interplay between patient-derived cancer cells and immune cells. …”
-
3025
Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter
Published 2025“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
-
3026
Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter
Published 2025“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
-
3027
Development and Use of a Galectin-1-Specific Nanobody for Tumor Imaging and Elucidating the Role of Galectin‑1 in Cancer
Published 2025“…Galectin-1 (GAL-1) plays a crucial role in cancer biology, especially in triple-negative breast cancer (TNBC), where it facilitates immune evasion and tumor progression. …”
-
3028
Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter
Published 2025“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
-
3029
Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter
Published 2025“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
-
3030
Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter
Published 2025“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
-
3031
Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter
Published 2025“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
-
3032
-
3033
Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter
Published 2025“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
-
3034
Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter
Published 2025“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
-
3035
Key safety measures including adverse events.
Published 2025“…<div><p>Background</p><p>The risk-to-benefit ratio of using combined oral contraceptive pills (COCPs) and/or metformin for comprehensive management of polycystic ovary syndrome (PCOS) in women with obesity is unclear. As there is a lack of robust evidence on the impact of these first-line medications on cardiovascular disease (CVD) risk, we compared the effect of COCPs, metformin or both on prevalence of metabolic syndrome (MetS) in participants with hyperandrogenic PCOS and hypothesized that COCPs would increase prevalence of MetS while metformin would decrease prevalence of MetS.…”
-
3036
-
3037
-
3038
Summary of KEGG enrichment analysis.
Published 2024“…While the expression levels of <i>IRS2</i>, <i>FOXO1</i>, and <i>ERK2</i> (<i>MAPK1</i>) were significantly decreased, the <i>SERPINF1</i> gene exhibited high expression simultaneously. pAAV-delivered <i>MIR-96</i> had no adverse effect on the viability of human RPE cells. …”
-
3039
-
3040